Optimal antithrombotic strategy in patients with atrial fibrillation beyond 1 year after drug-eluting stent implantation: Design and rationale of the randomized ADAPT AF-DES trial
Authors:
- 23 February 2024
- journal article
- research article
- Published by Elsevier in American Heart Journal
- Vol. 271, 48-54
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Drug-eluting or bare-metal stents for percutaneous coronary intervention: a systematic review and individual patient data meta-analysis of randomised clinical trialsThe Lancet, 2019
- Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial FibrillationNew England Journal of Medicine, 2019
- Open-Label Randomized Trial Comparing Oral Anticoagulation With and Without Single Antiplatelet Therapy in Patients With Atrial Fibrillation and Stable Coronary Artery Disease Beyond 1 Year After Coronary Stent ImplantationCirculation, 2019
- Label Adherence for Non-Vitamin K Antagonist Oral Anticoagulants in a Prospective Cohort of Asian Patients with Atrial FibrillationYonsei Medical Journal, 2019
- Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial FibrillationNew England Journal of Medicine, 2017
- Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCINew England Journal of Medicine, 2016
- Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trialThe Lancet, 2013
- Apixaban versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2011
- Rivaroxaban versus Warfarin in Nonvalvular Atrial FibrillationNew England Journal of Medicine, 2011
- A Multiple Testing Procedure for Clinical TrialsBiometrics, 1979